Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
IPO Year: 2015
Exchange: NASDAQ
Website: qualigeninc.com
PRE 14A - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
EFFECT - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
RW - Qualigen Therapeutics, Inc. (0001460702) (Filer)
S-1 - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
4 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)
Fastest customizable press release news feed in the world
Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback the golden moment CXC10 has been waiting for? The past 48 hours have been brutal for the entire crypto market. Amidst the market's turbulent volatility, approximately $16 billion in leveraged positions were forcibly liquidated, leaving many investors helpless to prevent a significant decline in their paper wealth. In times of widespread panic, we must remain calm. Declines often present opportunities. As Buffett famously said, "When others are greedy, I am fearful; when othe
New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen Therapertics"), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, from its client Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company. The total investment amounts to approximately $41 million
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or "the Company") today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("FF"), along with its Founder and Global Co-CEO YT Jia, President Jerry Wang, SIGN Foundation – a blockchain technology company backed by Binance Labs, Sequoia Capital (US, India, China), IDG, and Circle, and other leading investors. FF has invested $30 million in QLGN common and preferred stock, representing approximately 55% of pro forma beneficial ownership. YT Jia, has personally invested approxim
QLGN is expected to rebrand as CXC10 soon, reflecting its new strategic direction around crypto and web3 business. LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, today announced the successful closing of its announced strategic investment in Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a public company establishing new crypto and Web3-related adventures. The total investment amounts to approximately $41 million, led by FF with approximately $30 million, and an additional $4 million invested by FF Founder and Global
Faraday Future is making an investment of approximately $30 million in Qualigen Therapeutics ("QLGN"); FF Founder and Co-CEO YT Jia will invest approximately $4 million (via an FFGP loan) in QLGN with a two-year lockup.The strategic investment, which was announced at the Company's annual 919 event held in Los Angeles on Sept. 19, accelerates the progress of the "Dual-Flywheel & Dual-Bridge" Eco Strategy to maximize stockholder value. QLGN expects to rebrand as CXC10, focusing on three growth engines with six potential major products for crypto/Web3 ecosystem build-ip, targeting to become atop U.S. public company bridging Web2 and Web3, as well as AI and crypto.As of 6 p.m. on September 18, t
LOS ANGELES and CARLSBAD, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the "Agreement") for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a crypto and web3-related business. Upon completion of the required stockholder approval process, it is expected that QLGN will rebrand as CXC10, fully focusing on its three growth engines i
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or "Company"), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the "Agreement") for a private investment in public equity (PIPE) in QLGN's common stock and preferred stock, and will start a in Crypto and web3-related business. The PIPE financing is being led by Faraday Future and its Founder and Global Co-CEO YT Jia, together with other investors including SIGN Foundation, a blockchain
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company received the first notice from the Nasdaq Listings Qualifications office of the Nasdaq Stock Market LLC on July 23, 2025, informing the Company that as reflected in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on July 21, 2025, the Company failed to comply with the $2.5 million stockholder's equity required under Nasdaq Rule 5550(b)(1) (the "Equity Rule") or any alternative standard under
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placemen
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company" or "Qualigen") is announcing an update on patents granted in the first six months of 2025. The patent is Titled "Substitued Naphthalene Diimides and Their Use." The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing. Through validations and process across Europe these patents were granted and cover the majority of the Euoprean population. In total over 20 countries in Europe have patent coverage f
Live Leadership Updates
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the
CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t
New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off
Live finance-specific insights
Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-
Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition
CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Company's diversified product portfolio CARLSBAD, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its financial results for the second quarter ended June 30, 2022, and provides an update on its t
Transaction expected to significantly advance commercial readiness of NanoSynex's innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market Company to hold conference call today, June 2, 2022 at 1:00PM ET to discuss latest corporate developments CARLSBAD, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based de
Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million, compared to $3.2 million in the same nine-month period of the previous yearCash equivalents of approximately $12.3 million as of September 30, 2021 CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of adult and pediatric patients with rare cancers, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced its financial resul
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND in 2H21 for Treating Hospitalized COVID-19 Patients with QN-165Completed the R&D Evaluation and Qualification for QN-247; Expect to Finalize Formulation in 2H21Quarter-End Cash and Cash Equivalents Approximately $21.9 Million; Provides Sufficient Runway to Accomplish Key Inflection Points CARLSBAD, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral disea
This live feed shows all institutional transactions in real time.
SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)
SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)